Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
We evaluated the pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors (NNRTIs) in Ugandan adults. The study design was a three-period crossover study (3 tablets [600 mg of lopinavir/150 mg of ritonavir {600/150 mg}], 4 capsules [533/133 mg], and 2 t...
Հիմնական հեղինակներ: | Kityo, C, Walker, A, Dickinson, L, Lutwama, F, Kayiwa, J, Ssali, F, Nalumenya, R, Tumukunde, D, Munderi, P, Reid, A, Gilks, C, Gibb, D, Khoo, S |
---|---|
Ձևաչափ: | Journal article |
Լեզու: | English |
Հրապարակվել է: |
2010
|
Նմանատիպ նյութեր
-
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults.
: Byakika-Kibwika, P, և այլն
Հրապարակվել է: (2012) -
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
: Gilks, C, և այլն
Հրապարակվել է: (2012) -
Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects
: Cha YJ, և այլն
Հրապարակվել է: (2014-09-01) -
The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.
: Musiime, V, և այլն
Հրապարակվել է: (2014) -
Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers.
: German, P, և այլն
Հրապարակվել է: (2009)